| Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (NCT05308446) | National Cancer Institute (NCI) | 2022-07-19 |
| Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer (NCT04751370) | National Cancer Institute (NCI) | 2022-02-08 |
| Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer (NCT05081024) | OHSU Knight Cancer Institute | 2021-09-03 |
| Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer (NCT04406857) | National Cancer Institute (NCI) | 2021-03-17 |
| Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer (NCT04703101) | Jonsson Comprehensive Cancer Center | 2021-02-11 |
| LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer (NCT04616183) | M.D. Anderson Cancer Center | 2020-12-02 |
| SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial (NCT04599140) | M.D. Anderson Cancer Center | 2020-10-14 |
| Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer (NCT04362839) | City of Hope Medical Center | 2020-05-27 |
| Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer (NCT03992456) | Academic and Community Cancer Research United | 2020-04-24 |
| Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial (NCT03765736) | Academic and Community Cancer Research United | 2020-04-20 |
| TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study (NCT04109924) | Roswell Park Cancer Institute | 2019-12-27 |
| TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer (NCT04104139) | OHSU Knight Cancer Institute | 2019-12-11 |
| Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer (NCT03592641) | National Cancer Institute (NCI) | 2019-07-25 |
| Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment (NCT03516942) | ECOG-ACRIN Cancer Research Group | 2018-06-11 |
| Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer (NCT02107105) | M.D. Anderson Cancer Center | 2014-05-16 |
| Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer (NCT02874885) | M.D. Anderson Cancer Center | 2013-09-05 |